ECEESPE2025 ePoster Presentations Diabetes and Insulin (245 abstracts)
Increased utilization of diabetes technology and improved glycaemic control among children with type 1 diabetes in Hong Kong over the past 8 years
Sarah Poon 1 , Patrick Chan 2 , Betty But 3 , Shirley Wong 3 , Ivy Yam 3 , Pik To Cheung 4 , Queenie See 5 , Suki Chan 6 , Ho Chung Yau 6 , Eunice Wong 7 , LM Wong 7 , Cindy Chan 8 , Antony Fu 8 , Elaine Kwan 2 , Janez Tsui 2 , Tiffany Lai 9 , Priscilla Lo 9 , Yuen-Yu Lam 10 , Winnie Yuen 10 , Sammy Wong 11 , Jacky Chung 12 , Ching-Yin Lee 12 , MK Tay 13 & Joanna Tung 1
1Hong Kong Children’s Hospital, Hong Kong, Hong Kong; 2Pamela Youde Nethersole Eastern Hospital, Hong Kong, Hong Kong; 3Queen Elizabeth Hospital, Hong Kong, Hong Kong; 4The University of Hong Kong, Hong Kong, Hong Kong; 5Queen Mary Hospital, Hong Kong, Hong Kong; 6Prince of Wales Hospital, Hong Kong, Hong Kong; 7Tuen Mun Hospital, Hong Kong, Hong Kong; 8Princess Margaret Hospital, Hong Kong, Hong Kong; 9United Christian Hospital, Hong Kong, Hong Kong; 10Kwong Wah Hospital, Hong Kong, Hong Kong; 11Alice Ho Miu Ling Nethersole Hospital, Hong Kong, Hong Kong; 12Caritas Medical Centre, Hong Kong, Hong Kong; 13Tseung Kwan O Hospital, Hong Kong, Hong Kong
JOINT360
Background: New technological devices are increasingly used in the management of children with type 1 diabetes (T1D) worldwide and has been shown to improve glycaemic control and reduce risk of hypoglycaemia. In the past, there was considerable barrier in accessing these technologies locally. Territory-wide funding programme for CGMS and limited sponsorship for insulin pump have rolled out in the past few years. However, there is limited data on whether this has impacted glycaemic outcomes.
Method: This retrospective study assessed the use of CGMS and insulin pump in Hong Kong from 2017 to 2023. Data were retrieved from the Hong Kong Childhood Diabetes Registry. HbA1c over time, rates of DKA and severe hypogylcaemia (requiring glucagon injection/hospitalization) were evaluated. Additionally, HbA1c was compared between users versus non-users of CGMS and insulin pump in 2023.
Results: Table 1 showed an expansion of both regular CGMS and insulin pump use from 0% to 41.7% and 3.1% to 9.6% respectively from 2017 to 2023. There was significant improvement in HbA1c levels (P< 0.05) over the same period. No change in rates of DKA or severe hypogylcaemia was found. In 2023, regular CGM users demonstrated lower HbA1c levels compared to non-users (7.6 ± 1.2 vs 8.4 ± 1.8, P< 0.05). HbA1c was also lower among insulin pump users (7.5 ± 1.4 vs 8.0 ± 1.4, P< 0.05), with more achieving the target HbA1c < 7% (44.7% vs 19.8%, P< 0.05).
| Year | No of children with T1D | Regular CGM use (>80% time) (%) | Insulin pump (%) | Average HbA1c (%) | DKA | Severe hypoglycaemia |
| 2017 | 325 | 0 | 3.1% | 8.2 ± 1.7 | 8.3% | 1.2% |
| 2018 | 365 | 10.4% | 5.5% | 8.3 ± 1.8 | 2.5% | 0.8% |
| 2019 | 389 | 9.5% | 6.4% | 8.2 ± 1.8 | 3.1% | 2.3% |
| 2020 | 375 | 12.8% | 7.2% | 8.0 ± 1.6 | 2.4% | 2.9% |
| 2021 | 367 | 27.7% | 6.8% | 7.9 ± 1.5 | 3.0% | 0.8% |
| 2022 | 382 | 34.6% | 7.9% | 8.0 ± 1.6 | 2.9% | 1.3% |
| 2023 | 396 | 41.7% | 9.6% | 8.0 ± 1.5 | 2.8% | 2.3% |
Conclusion: While coverage of diabetes technologies remained much lower than that of many developed countries, utilization has expanded in the past 8 years in Hong Kong. Those who used these technologies had better glycaemic control. With this, policy change to allow broader coverage in children with T1D should be enforced.
Volume 110
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2025 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more